AN2 Therapeutics Inc.
ANTX | NASDAQ
$4.53
-$0.16 (-3.41%)
At close: Oct 30, 2026, 4:00 PM ET
$4.53
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:28 PM ET
-3.41%
(1D)No price chart data available for 1D timeframe.
Rating
35.2
+5.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #650/1028 (Top 63%)
Key Statistics
Market Data
Market Cap $170.95M
1D Range
4.31 4.76
52W Range
1.03 6.28
Valuation (TTM)
PE -4.23
PB 2.25
EV/EBITDA -2.46
Valuation (NTM)
Forward PE N/A
Forward PEG 0.21
Price Target $9.00
Cash Flow
FCF Yield -17.9%
SBC Adj. FCF Yield -20.7%
SBC Impact -15.1%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 39.1% |
17.9%
FCF 3Y | 5Y 35.6% |
1.2%
Returns
ROA -44.4%
ROE -53.5%
ROIC -51.0%
Financial Health
Net Cash
$78.39M
Current Ratio 14.32
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions....
Sector Healthcare
Industry Biotechnology
Employees 21
IPO Date Mar 25, 2022
Website www.an2therapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$9.00
Upside
+98.68%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ANTX